FEXO/M Tablets – Fexofenadine Hydrochloride 120 mg + Montelukast 10 mg
Composition: Each tablet contains Fexofenadine Hydrochloride 120 mg and Montelukast 10 mg.
Product Family: FEXO/M belongs to the antiallergic medicine category, combining a second-generation antihistamine with a leukotriene receptor antagonist.
Product Overview: FEXO/M combines fexofenadine and montelukast to help manage selected allergic conditions. Fexofenadine blocks histamine receptors to relieve allergy symptoms, while montelukast blocks leukotrienes involved in allergic inflammation and airway responses.
Indications: Depending on local product approval, FEXO/M may be prescribed for allergic rhinitis and associated symptoms, including sneezing, runny nose, nasal itching, and itchy or watery eyes, when combination therapy is considered appropriate.
Clinical Benefits: The combination provides complementary mechanisms of allergy symptom control. Fexofenadine helps relieve histamine-related symptoms, while montelukast may provide additional benefit for selected patients with allergic rhinitis. Treatment should be tailored to the patient's symptoms and clinical needs.
Dosage and Administration: The dosage should be determined by a qualified healthcare professional according to the patient's age, clinical condition, and approved product labeling. The 120 mg fexofenadine and 10 mg montelukast combination should not automatically be assumed suitable for every age group. Take the tablet as directed and do not exceed the prescribed dose.
Directions for Use: Take FEXO/M according to the prescribing instructions. Fexofenadine should be taken with water; avoid taking it with apple, orange, or grapefruit juice because these may reduce its absorption. Aluminum- or magnesium-containing antacids should generally be separated from fexofenadine by approximately two hours.
Precautions: Montelukast has a warning concerning serious neuropsychiatric events, including mood or behavioral changes and suicidal thoughts or actions. Seek prompt medical advice if these symptoms occur. For allergic rhinitis, montelukast is generally reserved for patients who do not respond adequately to or cannot tolerate alternative treatments. FEXO/M is not a rescue treatment for an acute asthma attack.
Drug Interactions: Fexofenadine absorption may be reduced by certain fruit juices and aluminum- or magnesium-containing antacids. Patients should inform their healthcare professional about all medicines and supplements they use, particularly before starting montelukast-containing therapy.
Usage During Pregnancy and Breastfeeding: Use during pregnancy or breastfeeding should be discussed with a healthcare professional, who can assess the benefits, risks, and suitability of each component. Patients should not start or discontinue treatment without medical advice.
Product Highlights: FEXO/M combines two antiallergic agents in one tablet to support symptom management in appropriately selected patients with allergic rhinitis. Its dual-action formulation offers a convenient treatment option when both ingredients are clinically indicated.
Product Summary: FEXO/M Tablets contain fexofenadine hydrochloride 120 mg and montelukast 10 mg to support the management of selected allergic conditions. Use should be guided by a qualified healthcare professional and the locally approved prescribing information.
Medical Notice: This description is intended for informational and professional website use. Confirm the registered brand name, approved indications, age restrictions, dosage, and local prescribing information before publication.
Company: INTERMED